CORAL GABLES, Fla., Nov. 3 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that Patrick J. McEnany, Chief Executive Officer, will be presenting an overview of the Company at the Rodman & Renshaw 10th Annual Global Investment Conference on Tuesday, November 11, 2008 at 10:45 am Eastern Time at the New York Palace Hotel in New York City.
Interested parties can access a live or archived web cast of the presentation at: http://www.wsw.com/webcast/rrshq14/cprx . The presentation will be archived for 90 days.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company
focused on the development and commercialization of prescription drugs for
the treatment of addiction and obsessive compulsive disorders. The Company
has obtained from Brookhaven National Laboratory an exclusive worldwide
license for Brookhaven's patent portfolio in the United States relating to
the right to use vigabatrin to treat a wide variety of substance addictions
and obsessive compulsive disorders. Catalyst has also been granted rights
to Brookhaven's vigabatrin-related foreign patents or patents pending in
more than 30 countries. The Company's initial product candidate based on
vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the
U.S. Food & Drug Administration (FDA) for the treatment of cocaine
addiction. This indicates that the FDA has recognized that CPP-109 is
intended for the treatment of a
|SOURCE Catalyst Pharmaceutical Partners, Inc.|
Copyright©2008 PR Newswire.
All rights reserved